Analysis of the Status of Chinese clinical practice guidelines development

Table 3 The scores of evaluating 7 guidelines by AGREE instrument

AGREE Domain	Asthma (1997)^a	COPD^b	Hyper-tension^c	AMI^d	Asthma (2003)^e	HAP^f	OSAHS^g	Average Score
scope and purpose (%)	16.7	27.8	66.7	55.6	16.7	72.2	33.3	41.3
stakeholder involvement (%)	4.2	0.0	54.2	12.5	0.0	0.0	0.0	10.1
rigor of development (%)	14.3	16.7	28.6	45.2	14.3	2.4	14.3	19.4
clarity and presentation (%)	95.8	95.8	100.0	83.3	83.3	75.0	95.8	89.9
Applicability (%)	16.7	27.8	50.0	16.7	22.2	11.1	16.7	23.0
editorial independence (%)	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0%
Spearman correlation coefficient	0.754	0.600	0.493	0.472	0.569	0.789	0.835
Sig.(2-tailed)	<0.01	<0.01	<0.05	<0.05	<0.01	<0.01	<0.01

Note:
a. the Guidelines for Prevention and Treatment of Bronchial Asthma (produced in 1997).
b. the Guidelines for Diagnosis and Treatment of COPD.
c. the Guidelines for Prevention and Treatment of Hypertension in China (produced in 1999).
d. the Guidelines for Diagnosis and Treatment of Acute Myocardial Infarction (AMI) [7].
e. the Guidelines for Prevention and Treatment of Bronchial Asthma (produced in 2003) [8].
f. the Guidelines for Diagnosis and Treatment of Hospital Acquired Pneumonia (HAP) [9].
g. the Guidelines for Diagnosis and Treatment of Obstructive Sleep Apnea/Hypopnea Syndrome (OSAHS-Draft) [10].

ISSN: 1472-6963